| Synvolux’ proprietary technology, SAINT (Synthetic, Amphiphilic, INTeractive), is based on a universal, highly developed platform of 100% synthetic delivery agents which display very high efficiencies with DNA, RNA (also siRNA), proteins and biopixels. The company’s patent portfolio covers more than 2 million chemical structures. Using proprietary linker technology and specific interacting agents we anticipate specific intracellular delivery of these macromolecules.
As demonstrated by Synvolux as well as by its customers, SAINT is superior in all head-to-head comparisons: in-vitro DNA transfection efficiencies are very high, transfection is detectable in otherwise hard to transfect cells, transfection is not inhibited by serum, little material (DNA, RNA) is required for effectiveness, and cell death is a limited issue. An important reason for the high degree of SAINT’s efficacy is its protection against degradation by DNAses and/or RNAses.
Toxicity assays have proven SAINT to be generally safe. In vivo efficacy has been proven in rodents
Chemical structures. A typical example of a SAINT molecule is:
|
